Engineering Abundance: Progressing Toward a Brighter Future!
Engineering Abundance: Regulatory Wins, Efficiency Records, and Steady Progress Fuel the Future!
Good Morning, Optimist! 🌅 September 4, 2026
Human ingenuity keeps compounding. Fresh regulatory green lights for fusion, record-breaking solar efficiencies in real-world-relevant formats, expanding gene therapy options for tough conditions, and documented species recoveries remind us that persistence and smart collaboration are steadily engineering a more abundant, resilient world. These signals show we’re not just hoping for breakthroughs—we’re building and deploying them.
Clean Energy: Tennessee’s Historic Fusion License; Perovskite Tandem and Module Efficiency Records
Tennessee became the first U.S. state to issue a commercial fusion license, granting Type One Energy approval for its Bull Run site. This milestone follows the Nuclear Regulatory Commission’s proposed framework and marks a concrete step from lab to licensed operation.[1]
On the solar front, Korean researchers at the Korea Institute of Energy Research (KIER) set a new world record of 26.7% efficiency (certified) for a sub-1 cm² perovskite-CIGS tandem solar cell, improving stability and reducing losses while enabling lightweight, flexible designs ideal for diverse applications.[2]
Separately, a Chinese team led by Nanjing University and Renshine Solar achieved a certified 24.0% efficiency on a large 810 cm² perovskite module—the highest for this format—using stable lead carboxylate passivators that enhance performance and durability.[3]
U.S. startup SunHydrogen exceeded 10% solar-to-hydrogen efficiency with 100 cm² modules in independent testing, advancing practical green hydrogen production.[4]
These wins highlight fusion’s regulatory maturation alongside solar’s rapid efficiency gains in scalable formats.
Gene Therapies: First Treatment for Glycogen Storage Disease Type Ia; New Oncolytic Option for Advanced Melanoma
The FDA granted accelerated approval to Genglycos (pariglasgene brecaparvovec), the first gene therapy for glycogen storage disease type Ia (GSDIa, or von Gierke disease). This one-time AAV-based treatment delivers a functional G6PC gene to the liver, significantly reducing patients’ reliance on cornstarch while addressing the root cause in adults and children ages 8 and older.[5]
Additionally, the FDA approved Tudriqev (vusolimogene oderparepvec), an engineered oncolytic viral immunotherapy, in combination with nivolumab for adults with unresectable advanced melanoma that has progressed on PD-1 inhibitors. In trials, about one in four patients responded, with responses lasting a median of roughly 14 months—offering meaningful new hope for this challenging population.[6]
These approvals expand precise genetic and viral medicines to more patients and conditions.
Conservation: Documented Progress Across Species and Habitats
Endangered species continue showing measurable gains under sustained efforts. Reports highlight population increases and recoveries for species like whooping cranes (now over 250 in the wild thanks to long-term programs), Kemp’s ridley sea turtles, and others benefiting from habitat protection, predator control, and reintroductions.[7]
Broader initiatives, including the U.K.’s record £90 million Species Recovery Programme investment and ongoing rewilding successes (such as black rhinos returning to Zimbabwe’s Matusadona National Park after decades), demonstrate that targeted action reverses declines and restores ecosystems.[8]
These examples underscore nature’s resilience when given protection and support.
Momentum Toward Greater Abundance
From Tennessee’s pioneering fusion license and fresh perovskite efficiency records to the first approved therapy for GSDIa and Tudriqev’s melanoma approval, today’s updates reflect accelerating regulatory, technical, and ecological progress. Each advance—whether in megawatts enabled, patients helped, or populations rebounding—reinforces the others, turning ambitious ideas into tangible results.
We measure this in licenses granted, efficiency percentages certified, and species on the mend. The trajectory points to engineered abundance.
“The best way to predict the future is to create it.” – Inspired by Peter Diamandis
Rise ready—the momentum is building! 🌍✨
Sources (for easy verification):
- Tennessee fusion license: American Nuclear Society / Nuclear Newswire (Sept 2, 2026)
- KIER 26.7% perovskite-CIGS tandem: pv magazine (Sept 2, 2026)
- Chinese 24% large perovskite module: PV Magazine / The Cool Down (Sept 3, 2026)
- SunHydrogen solar-to-hydrogen: pv magazine USA (Sept 1, 2026)
- Genglycos GSDIa approval: FDA (Aug 19, 2026)
- Tudriqev melanoma approval: FDA (Aug 2026 announcement)
- Species recovery progress: EDF / various 2026 reports
- Broader conservation: U.K. GOV.UK, rewilding updates (2026)
Stay curious and optimistic—more good news tomorrow!